(Q50155002)

26 February 2018

title

Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database. (English)

1 reference

26 February 2018

1 reference

Buchbinder R

1

1 reference

26 February 2018

March L

2

1 reference

26 February 2018

Lassere M

3

1 reference

26 February 2018

Briggs AM

4

1 reference

26 February 2018

Portek I

5

1 reference

26 February 2018

Reid C

6

1 reference

26 February 2018

Meehan A

7

1 reference

26 February 2018

Henderson L

8

1 reference

26 February 2018

Wengier L

9

1 reference

26 February 2018

van den Haak R

10

1 reference

26 February 2018

publication date

15 June 2007

1 reference

26 February 2018

Internal Medicine Journal

published in

1 reference

26 February 2018

volume

37

1 reference

26 February 2018

issue

9

1 reference

26 February 2018

page(s)

591-600

1 reference

26 February 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Etanercept plus standard therapy for Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

The role of the Australian Adverse Drug Reactions Advisory Committee (ADRAC) in monitoring drug safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Postmarketing surveillance--lack of vigilance, lack of trust.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

The British Society for Rheumatology biologics register

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01431.X

10.1111/J.1445-5994.2007.01431.X

21 January 2018

Identifiers

DOI

1 reference

26 February 2018

1 reference

26 February 2018